CLAIMS

1. A composition comprising an expression system comprising an adenovirus viral vector comprising polynucleotides encoding pneumovirus proteins, and a pharmaceutically acceptable carrier and/or excipient, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, a second polynucleotide encoding at least one protein, peptide or variant thereof, which induces an anti-pathogenic B cell response, and a third polynucleotide encoding a protein, peptide or variant thereof, which induces a T cell response, wherein:

   the pneumovirus is human respiratory syncytical virus (RSV);

   the protein, peptide or variant thereof which induces a T cell response, encoded by the first polynucleotide, is a non-structural and/or internal protein of RSV selected from the group consisting of Matrix proteins M and M2;

   the protein, peptide or variant thereof which induces an anti-pathogenic B cell response, encoded by the second polynucleotide, is a structural and/or surface protein of RSV which is the fusion protein (F), and;

   the protein, peptide or variant thereof which induces a T cell response, encoded by the third polynucleotide, is a non-structural and/or internal protein of RSV which is the nucleoprotein N; and

   the first polynucleotide, the second polynucleotide and the third polynucleotide are linked such that they are expressed as an artificial polyprotein.

2. The composition of claim 1, wherein a polynucleotide which encodes a cleavage site is positioned between the first polynucleotide and the second polynucleotide.

3. The composition of claim 2, wherein the cleavage site is a self-cleaving site or an endopeptidase cleavage site, wherein the self-cleaving site is selected from the group consisting of a viral 2A peptide or 2A-like peptide of Picornavirus, insect viruses, Aphtoviridae, Rotaviruses and Trypanosoma.

4. The composition of claim 3 wherein the 2A cleavage site is the 2A peptide of foot and mouth disease virus.

5. The composition of any of claims 1 to 4, wherein a polynucleotide encoding a linker, such as a flexible linker, is positioned between the second polynucleotide and the third polynucleotide.

6. The composition of any of claims 1 to 5, wherein the viral vector is selected from the group consisting of PanAd1, PanAd2, PanAd3, ChAd55, ChAd 73, ChAd83, ChAd146, ChAd147, ChAd3, ChAd4, ChAd5, ChAd6, ChAd7, ChAd8, ChAd9, ChAd10, ChAd11, ChAd16, ChAd17, ChAd19, ChAd20, ChAd22, ChAd24, ChAd26, ChAd30, ChAd31, ChAd37, ChAd38, ChAd44, ChAd63 and ChAd82.

7. The composition of any of claims 1 to 6, comprising a further active ingredient, preferably selected from the group consisting of an adjuvant and an active ingredient.

8. The composition according to any one of claims 1 to 7, for use in the treatment or prevention of a disease caused by RSV infection.

9. The use of the composition according to any one of claims 1 to 7 in the manufacture of a medicament for the treatment or prevention of a disease caused by RSV infection.